drugset / Trial / NCT07226817

A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

NCT07226817

Phase 1 Recruiting 140 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to evaluate the relative bioavailability (rBA) of multiple test tablet formulations of BMS-986435 compared to an equal dose of the BMS-986435 reference tablet formulation. The effect of food on the selected BMS-986435 tablet formulation will also be evaluated.

Timeline

Start
2025-11-12
Primary completion
2026-12-17
Completion
2026-12-17

Drugs

EvaluationDrugModalityDoseRoute
Subject DELOCAMTEN Small molecule

Indications

No indication recorded.